<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027963</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-N00C3</org_study_id>
    <secondary_id>CDR0000069098</secondary_id>
    <secondary_id>NCCTG-CCC-0020</secondary_id>
    <secondary_id>NCI-P01-0196</secondary_id>
    <nct_id>NCT00027963</nct_id>
  </id_info>
  <brief_title>Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy</brief_title>
  <official_title>The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Gabapentin may be effective in relieving pain and other symptoms of peripheral&#xD;
      neuropathy. It is not yet known if gabapentin is effective in treating peripheral neuropathy&#xD;
      in cancer patients undergoing chemotherapy.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of gabapentin in treating&#xD;
      pain and other symptoms of peripheral neuropathy in cancer patients undergoing chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether gabapentin improves the pain and other symptoms in cancer patients&#xD;
           with chemotherapy-induced peripheral neuropathy.&#xD;
&#xD;
        -  Determine the effect of this drug on symptom distress, mood states, functional&#xD;
           abilities, and overall quality of life in these patients.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to neurotoxic chemotherapy (active vs nonactive and discontinued vs&#xD;
      completed) and neurotoxic chemotherapeutic agents (vinca alkaloids vs taxanes vs&#xD;
      platinum-based compounds vs combination of two or more of the above agents). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive titrating doses of oral gabapentin twice daily and then three&#xD;
           times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three&#xD;
           times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.&#xD;
&#xD;
        -  Arm II: Patients receive titrating doses of oral placebo and then a fixed dose of oral&#xD;
           placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.&#xD;
&#xD;
      Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain and symptoms</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Neurotoxicity</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.&#xD;
Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.&#xD;
Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gabapentin</intervention_name>
    <arm_group_label>gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Has received or is currently receiving neurotoxic chemotherapy, including taxanes&#xD;
             (e.g., paclitaxel or docetaxel), platinum-based compounds (e.g., carboplatin,&#xD;
             cisplatin, or oxaliplatin), or vinca alkaloids (e.g., vincristine or vinblastine)&#xD;
&#xD;
          -  Pain or symptoms of peripheral neuropathy of at least 1 month duration attributed to&#xD;
             chemotherapy-induced peripheral neuropathy&#xD;
&#xD;
               -  Average daily pain rating of at least 4 out of 10 using the pain numerical rating&#xD;
                  scale (where 0 is no pain and 10 is the worst pain possible) OR&#xD;
&#xD;
               -  Evidence of peripheral neuropathy of at least grade 1 out of 3 by ECOG Common&#xD;
&#xD;
                    -  Toxicity Criteria for sensory neuropathy&#xD;
&#xD;
          -  No other identified causes of painful paresthesia existing prior to chemotherapy&#xD;
&#xD;
               -  No radiotherapy-induced or malignant plexopathy&#xD;
&#xD;
               -  No lumbar or cervical radiculopathy&#xD;
&#xD;
               -  No pre-existing peripheral neuropathy of another etiology, including:&#xD;
&#xD;
                    -  B12 deficiency&#xD;
&#xD;
                    -  AIDS&#xD;
&#xD;
                    -  Monoclonal gammopathy&#xD;
&#xD;
                    -  Diabetes&#xD;
&#xD;
                    -  Heavy metal poisoning&#xD;
&#xD;
                    -  Amyloidosis&#xD;
&#xD;
                    -  Syphilis&#xD;
&#xD;
                    -  Hyperthyroidism or hypothyroidism&#xD;
&#xD;
                    -  Inherited neuropathy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times upper limit of normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior allergic reaction or intolerance to gabapentin&#xD;
&#xD;
          -  No significant psychiatric illness (e.g., mania, psychosis, or schizophrenia) that&#xD;
             would preclude study compliance&#xD;
&#xD;
          -  No extreme difficulty swallowing pills&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  More than 30 days since prior investigational agent for pain control&#xD;
&#xD;
          -  Concurrent selective serotonin reuptake inhibitors allowed&#xD;
&#xD;
          -  Concurrent nonsteroidal anti-inflammatory drugs allowed&#xD;
&#xD;
          -  No concurrent tricyclic antidepressant (e.g., amitriptyline, nortriptyline, or&#xD;
             desipramine)*&#xD;
&#xD;
          -  No concurrent monoamine oxidase inhibitor*&#xD;
&#xD;
          -  No concurrent opioid analgesic*&#xD;
&#xD;
          -  No other concurrent adjuvant analgesic (e.g., anticonvulsant, clonazepam, or&#xD;
             mexiletine)*&#xD;
&#xD;
          -  No concurrent topical analgesics (e.g., lidocaine gel or lidocaine patch)*&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
&#xD;
          -  No concurrent investigational agent for pain control NOTE: * For pain or symptoms due&#xD;
             to chemotherapy-induced peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Loprinzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Mayo Clinic Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Health Plaza</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY; North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007 Nov 1;110(9):2110-8.</citation>
    <PMID>17853395</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurotoxicity</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

